Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 5;10(4):605. doi: 10.3390/jcm10040605

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Overview of symptoms of the acute COVID-19 disease course in AID patients. Acute COVID-19 disease course was less severe in the three adolescent AID patients with canakinumab maintenance treatment as compared to the adult patient treated with methotrexate. Particularly patient 4, who was treated with daily colchicine and who had received canakinumab 150 mg s.c. 4 days before COVID-19 was confirmed, had a short and mild disease course. Abbreviations: CAN: Canakinumab; CT: Computed tomography; COVID-19: Coronavirus disease 2019; GI-S.: Gastrointestinal symptoms such as nausea, diarrhea, emesis, abdominal pain; MTX: Methotrexate. Legend: ⇨ ongoing disease symptoms on day 22 after COVID-19 onset.